Display options
Share it on

Cardiol Res Pract. 2010 Aug 24;2010. doi: 10.4061/2010/919783.

C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia.

Cardiology research and practice

Aimé Bonny, Nicolas Lellouche, Ivo Ditah, Françoise Hidden-Lucet, Martial T Yitemben, Benjamin Granger, Fabrice Larrazet, Robert Frank, Guy Fontaine

Affiliations

  1. Service de Cardiologie, Hôpital Saint Camille, 2 rue des pères camilliens, 94366 Bry-sur-Marne, France.

PMID: 20885777 PMCID: PMC2943123 DOI: 10.4061/2010/919783

Abstract

Background. The relationship between C-reactive protein (CRP) elevation and ventricular tachycardia (VT) in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is unclear. Methods and Results. In 91 consecutive patients with either ARVD/C with or without VT (cases) or idiopathic right ventricular outflow tract (RVOT) tachycardia (controls), blood sampling were taken to determine CRP levels. In ARVD/C patients with VT, we analyzed the association between VT occurrences and CRP level. Sixty patients had ARVD/C, and 31 had idiopathic RVOT VT. Patients with ARVD/C had a significant higher level of CRP compared to those with RVOT VT (3.5 ± 4.9 versus 1.1 ± 1.2 mg/l, P = .0004). In ARVD/C group, 77%, (n = 46) patients experienced VT. Of these, 37% (n = 17) underwent blood testing for CRP within 24 h after the onset of VT and the remaining 63% (n = 29) after 24 h of VT reduction. CRP level was similar in ARVD/C patients with or without documented VT (3.6 ± 5.1 mg/l versus 3.1 ± 4.1 mg/l, P = .372). However, in patients with ARVD/C and documented VT, CRP was significantly higher when measured within 24 hours following VT in comparison to that level when measured after 24 h (4.9 ± 6.2 mg/l versus 3.0 ± 4.4 mg/l, P = .049). Conclusion. Inflammatory state is an active process in patients with ARVD/C. Moreover, there is a higher level of CRP in patients soon after ventricular tachycardia, and this probably tends to decrease after the event.

References

  1. Heart. 2000 May;83(5):588-95 - PubMed
  2. Circulation. 2000 Mar 21;101(11):E101-6 - PubMed
  3. J Am Coll Cardiol. 2004 Jun 16;43(12):2305-13 - PubMed
  4. Scand J Clin Lab Invest. 2009;69(3):425-32 - PubMed
  5. J Am Coll Cardiol. 2000 Sep;36(3):766-72 - PubMed
  6. Eur Heart J. 2007 Mar;28(5):589-600 - PubMed
  7. Circulation. 1996 Sep 1;94(5):983-91 - PubMed
  8. N Engl J Med. 2000 Mar 23;342(12):836-43 - PubMed
  9. Cytokine. 2009 Sep;47(3):166-72 - PubMed
  10. N Engl J Med. 2004 Dec 16;351(25):2599-610 - PubMed
  11. Annu Rev Med. 2010;61:233-53 - PubMed
  12. Arch Mal Coeur Vaiss. 1978 Sep;71(9):963-72 - PubMed
  13. N Engl J Med. 2009 Apr 9;360(15):1526-38 - PubMed
  14. N Engl J Med. 2008 Nov 20;359(21):2195-207 - PubMed
  15. Am J Cardiol. 2005 Feb 15;95(4):490-1 - PubMed
  16. J Am Coll Cardiol. 2006 Feb 21;47(4):769-73 - PubMed
  17. Circulation. 2006 Feb 14;113(6):876-90 - PubMed
  18. Int J Cardiol. 2002 Dec;86(2-3):123-30 - PubMed
  19. J Rheumatol. 2007 Jul;34(7):1459-64 - PubMed
  20. J Card Fail. 2009 Nov;15(9):775-81 - PubMed
  21. Eur Heart J. 1991 Aug;12 Suppl D:22-5 - PubMed
  22. Eur Heart J. 1993 May;14(5):717-20 - PubMed
  23. Circulation. 2002 Jul 16;106(3):388-91 - PubMed
  24. Am J Pathol. 1998 Feb;152(2):479-84 - PubMed
  25. Circulation. 2003 Jul 1;107(25):3133-40 - PubMed
  26. Circulation. 1982 Feb;65(2):384-98 - PubMed
  27. Clin Cardiol. 2009 Sep;32(9):E45-50 - PubMed
  28. Clin Cardiol. 2007 Aug;30(8):408-13 - PubMed
  29. J Am Coll Cardiol. 2003 Jul 2;42(1):81-7 - PubMed
  30. N Engl J Med. 1988 Jan 21;318(3):129-33 - PubMed
  31. Circulation. 2001 Feb 27;103(8):1044-7 - PubMed

Publication Types